20-05-2014
NZP will be at BIO 2014

We are pleased to announce that New Zealand Pharmaceuticals Ltd and Dextra will attend BIO 2014 in San Diego, CA, June 23 -26, 2014.   Please arrange to meet us by direct...

Read more
03-03-2014
ManNAc in Human Plasma

Method Development and Validation for the Quantitation of ManNAc in Human Plasma Using HILIC LC-MS/MS  Yifan Shi1; Meng Fang1; Michael Zhang1; Yinghe Li1; Amy Wang2; Ed Kerns2; Nuria CarrilloCarrasco2; Xin Xu2;...

Read more
01-08-2013
NZP will be at Pharma ChemOutsourcing 2013

We are pleased to announce that NZP and Dextra laboratories Ltd will attend Pharma ChemOutsourcing, www.chemoutsourcing.com in Long Branch, NJ 07740, on September 17-19, 2013. Please arrange to meet us by...

Read more
10-07-2013
DEX-M74 Licensing

NZP is presenting on the application of DEX-M74 ManNAc as a potential therapy for HIBM (GNE myopathy) and kidney glomerular diseases at the NCATS R&D Day on Thursday, September 12,...

Read more
07-05-2013
US Patent Issued

New Zealand Pharmaceuticals Ltd is pleased to announce that the U.S. patent 8,410,063, entitled “N-acetyl mannosamine as a therapeutic agent” was issued on April 2, 2013. The invention relates to...

Read more
14-02-2013
Application of N-acetylmannosamine

The application of N-acetylmannosamine to the mammalian cell culture production of recombinant human glycoproteins   Selwyn C Yorke   Keywords: N-acetylmannosamine, sialylation, glycoproteins.   This mini-review covers recent developments in the understanding, role and value of...

Read more
08-02-2013
NZP is certified ISO 14001
NZP is certified ISO 14001

New Zealand Pharmaceuticals Ltd is proud to announce that is has been audited by TELARC and achieved its first ISO 14001 certification. In 2010, NZP implemented a specific program within...

Read more
07-02-2013
Informex 2013

  We are pleased to announce that Dextra laboratories Ltd and NZP will attend Informex USA 2013 in Anaheim CA, on February 20 & 21, 2013.   Please arrange to meet us by...

Read more
04-12-2012
Tax Credit Certificate - France

NZP is pleased to announce that Dextra has just received the French Ministére de L’Enseignement Supérieur et de la Recherche Tax Credit certificate.  This is good news for any business...

Read more
20-11-2012
One Million Hours of No Lost Time

New Zealand Pharmaceuticals Ltd Celebrates One Million Hours of No Lost Time New Zealand Pharmaceuticals Ltd (NZP), a global leader in Bile Acids manufacturing has proven itself to be a model...

Read more
19-11-2012
IBM, HIBM and GNE Myopathy

There is confusion in some circumstances with the very similar names of two quite different medical disorders; Inclusion Body Myositis and Hereditary Inclusion Body Myopathy. This press release is to...

Read more
27-10-2012
New Research Published

New research published on potential mannosamine therapy for HIBM (GNE myopathy) and kidney glomerular disease   “Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy”,...

Read more
28-09-2012
Trial for Rare Degenerative Muscle Disease Treatment

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health...

Read more
28-09-2012
Phase I Clinical Trial

New Zealand Pharmaceuticals Ltd Announces a phase I clinical trial using DEX-M74 to treat a rare degenerative muscle disease Palmerston North, New Zealand, September 26, 2012 — New Zealand Pharmaceuticals Ltd...

Read more
25-09-2012
Lithocholic Acid - New Product

There is growing interest in the research community regarding new agonists that activate the FXR, LXR and TGR5 nuclear receptors. These receptors are linked to a wide range of disorders from...

Read more
12-06-2012
NZP will be at BIO 2012

We are pleased to announce that New Zealand Pharmaceuticals Ltd and Dextra will attend BIO 2012 in Boston, MA, on June 18-2130, 2012. Please arrange to meet us by direct email...

Read more
26-04-2012
New Drug Development Partnership

National Human Genome Research Institute (NHGRI) (Bethesda, MD; www.genome.gov) and New Zealand Pharmaceuticals Ltd (NZP) (Palmerston North, New Zealand; www.nzp.co.nz) have partnered on a drug development project. The goal is...

Read more
01-03-2012
Andy Lewis will present a Plenary at NZ Bio

NZP’s CEO, Andy Lewis, will be a plenary speaker at the NZ Bio conference on Tuesday 27 March 2012, www.nzbio2012.co.nz to discuss the development of NZP’s new drug candidate, DEX-M74...

Read more
28-02-2012
Natural History Study of Patients with HIBM

The U.S. National Institutes of Health Clinical Center (NIH CC) in Bethesda, Maryland, U.S. is running a natural history study on patients with hereditary inclusion body myopathy (HIBM).  This study...

Read more
15-12-2011
Orphan Drug Designation

New Zealand Pharmaceuticals Ltd receives Orphan Drug Designation from the U.S. Food and Drug Administration for DEX-M74, a Treatment for Hereditary Inclusion Body Myopathy (HIBM) Palmerston North, New Zealand, December 15,...

Read more
17-11-2011
Taurochenodeoxycholic acid - new product

There is a groundswell of interest in the research community regarding new agonists that activate the FXR, LXR and TGR5 nuclear receptors. These receptors are linked to a wide range...

Read more
17-08-2011
NZP Announces Collaboration with the NHGRI

New Zealand Pharmaceuticals Announces Collaboration with the NHGRI to Develop DEX-M74 as a Treatment for Hereditary Inclusion Body Myopathy (HIBM)

Read more
16-08-2011
NZP Awards Scholarships to Chemistry Students

NZP 300-level Bursary The Bursary was awarded jointly to Heather Jameson and David Nixon. Both these candidates attended secondary school in Palmerston North and then chose to study at Massey University...

Read more
29-04-2011
In the Pipeline - Waste Water Discharge Management

The end of New Zealand Pharmaceuticals' wastewater discharge directly into the Manawatu River is a milestone for the waterway.

Read more
01-01-2011
New Sustainability Program Launch

NZP has always endeavoured to engage in sustainable business practices, recognizing that potentially, without intervention, demand will eventually exceed supply of eco-system resources. Interestingly, NZP itself was built on the...

Read more